Authors:
BRICKL R
HEINZEL G
WEISENBERGER H
SCHUBERT H
RUTSCH W
ROTH W
Citation: R. Brickl et al., PK PD SIMULATIONS AS A TOOL FOR RATIONAL DESIGN OF CLINICAL DOSAGE REGIMENS - AN EXAMPLE WITH FRADAFIBAN/, International journal of clinical pharmacology and therapeutics, 35(10), 1997, pp. 475-480
Authors:
MULLER TH
WEISENBERGER H
BRICKL R
NARJES H
HIMMELSBACH F
KRAUSE J
Citation: Th. Muller et al., PROFOUND AND SUSTAINED INHIBITION OF PLATELET-AGGREGATION BY FRADAFIBAN, A NONPEPTIDE PLATELET GLYCOPROTEIN IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG, LEFRADAFIBAN, IN MEN/, Circulation, 96(4), 1997, pp. 1130-1138
Authors:
VONNICOLAI H
BRICKL R
ESCHEY H
GREISCHEL A
HEINZEL G
KONIG E
LIMMER J
RUPPRECHT E
Citation: H. Vonnicolai et al., DURATION OF ACTION AND PHARMACOKINETICS OF THE ORAL ANTIDIABETIC DRUGGLIQUIDONE IN PATIENTS WITH NON-INSULIN-DEPENDENT (TYPE-2) DIABETES-MELLITUS, Arzneimittel-Forschung, 47(3), 1997, pp. 247-252
Authors:
MULLER TH
WEISENBERGER H
BRICKL R
KIRCHNER M
NARJES H
HIMMELSBACH F
GUTH B
KRAUSE J
Citation: Th. Muller et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF BIBU-52, A PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG BIBU-104 IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1445-1445
Authors:
MULLER TH
WEISENBERGER H
BRICKL R
RUHR K
NARJES H
HIMMELSBACH F
Citation: Th. Muller et al., ANTI-AGGREGATORY PROFILE OF THE PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST BIBU-52 IN EX-VIVO STUDIES IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1447-1447